Literature DB >> 19953341

A subtle alternative splicing event of the Na(V)1.8 voltage-gated sodium channel is conserved in human, rat, and mouse.

Jana Schirmeyer1, Karol Szafranski, Enrico Leipold, Christian Mawrin, Matthias Platzer, Stefan H Heinemann.   

Abstract

The voltage-gated sodium channel subtype Na(V)1.8 (SCN10A) is exclusively expressed in dorsal root ganglia (DRG) and plays a critical role in pain perception. We isolated mRNA from human, rat, and mouse DRGs and screened for alternatively spliced isoforms of the SCN10A mRNA using 454 sequencing. In all three species, we found an event of subtle alternative splicing at a NAGNAG tandem acceptor that results in isoforms including or lacking glutamine 1030 (Na(V)1.8+Q and Na(V)1.8-Q, respectively) within the cytoplasmic loop between domains II and III. The relative amount of Na(V)1.8-Q mRNA in adult DRG was measured with 14.1 +/- 0.1% in humans and 11.2 +/- 0.2% in rats. This is in contrast to an abundance of 64.3 +/- 0.3% in mouse DRG. Thus, the NAGNAG tandem acceptor in SCN10A is conserved among rodents and humans but its alternative usage apparently occurs with species-specific abundance. Analysis of human Na(V)1.8+Q and -Q isoforms in whole-cell patch-clamp experiments after heterologous expression in the neuroblastoma cell line Neuro-2A revealed no obvious impact of the splicing event on channel function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19953341     DOI: 10.1007/s12031-009-9315-3

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  14 in total

1.  Modulation of cloned skeletal muscle sodium channels by the scorpion toxins Lqh II, Lqh III, and Lqh alphaIT.

Authors:  H Chen; D Gordon; S H Heinemann
Journal:  Pflugers Arch       Date:  2000-02       Impact factor: 3.657

2.  Identification of a conserved ankyrin-binding motif in the family of sodium channel alpha subunits.

Authors:  Guy Lemaillet; Barbara Walker; Stephen Lambert
Journal:  J Biol Chem       Date:  2003-04-25       Impact factor: 5.157

3.  Partial expression defect for the SCN5A missense mutation G1406R depends on splice variant background Q1077 and rescue by mexiletine.

Authors:  Bi-Hua Tan; Carmen R Valdivia; Chunhua Song; Jonathan C Makielski
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-04-21       Impact factor: 4.733

4.  Genomic splice-site analysis reveals frequent alternative splicing close to the dominant splice site.

Authors:  Yimeng Dou; Kristi L Fox-Walsh; Pierre F Baldi; Klemens J Hertel
Journal:  RNA       Date:  2006-10-19       Impact factor: 4.942

Review 5.  Modification of alternative splicing pathways as a potential approach to chemotherapy.

Authors:  D Mercatante; R Kole
Journal:  Pharmacol Ther       Date:  2000-03       Impact factor: 12.310

6.  Frequent occurrence of protein isoforms with or without a single amino acid residue by subtle alternative splicing: the case of Gln in DRPLA affects subcellular localization of the products.

Authors:  Keiko Tadokoro; Mayu Yamazaki-Inoue; Maki Tachibana; Mina Fujishiro; Kazuaki Nagao; Masashi Toyoda; Miwako Ozaki; Masami Ono; Nobuhiro Miki; Toshiyuki Miyashita; Masao Yamada
Journal:  J Hum Genet       Date:  2005-08-10       Impact factor: 3.172

7.  A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels.

Authors:  Jonathan C Makielski; Bin Ye; Carmen R Valdivia; Matthew D Pagel; Jielin Pu; David J Tester; Michael J Ackerman
Journal:  Circ Res       Date:  2003-09-18       Impact factor: 17.367

8.  Transcriptome and genome conservation of alternative splicing events in humans and mice.

Authors:  C W Sugnet; W J Kent; M Ares; D Haussler
Journal:  Pac Symp Biocomput       Date:  2004

Review 9.  Evolution of voltage-gated Na(+) channels.

Authors:  Alan L Goldin
Journal:  J Exp Biol       Date:  2002-03       Impact factor: 3.312

10.  Novel isoforms of the sodium channels Nav1.8 and Nav1.5 are produced by a conserved mechanism in mouse and rat.

Authors:  Niall C H Kerr; Fiona E Holmes; David Wynick
Journal:  J Biol Chem       Date:  2004-03-26       Impact factor: 5.157

View more
  6 in total

1.  Mechanism and molecular basis for the sodium channel subtype specificity of µ-conopeptide CnIIIC.

Authors:  René Markgraf; Enrico Leipold; Jana Schirmeyer; Marianne Paolini-Bertrand; Oliver Hartley; Stefan H Heinemann
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  Exon 11 skipping of SCN10A coding for voltage-gated sodium channels in dorsal root ganglia.

Authors:  Jana Schirmeyer; Karol Szafranski; Enrico Leipold; Christian Mawrin; Matthias Platzer; Stefan H Heinemann
Journal:  Channels (Austin)       Date:  2014       Impact factor: 2.581

3.  Functional characterization of SCN10A variants in several cases of sudden unexplained death.

Authors:  Ivan Gando; Nori Williams; Glenn I Fishman; Barbara A Sampson; Yingying Tang; William A Coetzee
Journal:  Forensic Sci Int       Date:  2019-05-29       Impact factor: 2.395

4.  A novel µ-conopeptide, CnIIIC, exerts potent and preferential inhibition of NaV1.2/1.4 channels and blocks neuronal nicotinic acetylcholine receptors.

Authors:  Philippe Favreau; Evelyne Benoit; Henry G Hocking; Ludovic Carlier; Dieter D' hoedt; Enrico Leipold; René Markgraf; Sébastien Schlumberger; Marco A Córdova; Hubert Gaertner; Marianne Paolini-Bertrand; Oliver Hartley; Jan Tytgat; Stefan H Heinemann; Daniel Bertrand; Rolf Boelens; Reto Stöcklin; Jordi Molgó
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

5.  Contribution of tetrodotoxin-resistant persistent Na+ currents to the excitability of C-type dural afferent neurons in rats.

Authors:  Michiko Nakamura; Il-Sung Jang
Journal:  J Headache Pain       Date:  2022-06-28       Impact factor: 8.588

Review 6.  Alternative RNA splicing: contribution to pain and potential therapeutic strategy.

Authors:  Lucy F Donaldson; Nicholas Beazley-Long
Journal:  Drug Discov Today       Date:  2016-06-18       Impact factor: 7.851

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.